Gilead Sciences Inc Form 4 Filings

Gilead Sciences Chief Medical Officer Dietmar Berger acquired 8,530 shares of common stock at no cost through a grant/award transaction. These shares relate to specific tranches of performance share awards originally granted on March 10, 2025.

The performance-vesting requirement for these tranches was satisfied on February 27, 2026, when the Compensation and Talent Committee certified that the performance goals were met. Following this award, Berger directly holds a total of 17,912 Gilead common shares.

Gilead Sciences executive reports stock award vesting. EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M acquired 470 shares of Gilead common stock on the reported date at a stated price of $0.00 per share, increasing directly held common stock to 4,414 shares.

The shares relate to specific tranches of performance share awards originally granted on March 10, 2025. These tranches were subject to both performance-vesting and service-vesting conditions, with the performance goals certified as attained by the Compensation and Talent Committee on the reported vesting date.

Gilead Sciences Chairman & CEO Daniel O'Day reported both an equity award and stock sales. He acquired 38,396 shares of common stock at $0.00 per share as part of performance share awards granted on March 10, 2025, which vested after the compensation committee certified performance goals.

On the same date, he sold a total of 10,000 common shares in open-market transactions at prices ranging from about $143.63 to $145.71, under a Rule 10b5-1 trading plan adopted on February 28, 2025. After these transactions, he directly held 642,308 shares of Gilead common stock.

Gilead Sciences executive Johanna Mercier reported a mix of option exercises and stock sales. On February 17, 2026, she exercised 25,000 non-qualified stock options, acquiring 25,000 shares of common stock at $66.64 per share through a derivative exercise.

That same day, she sold 18,405 shares at $154.182, 9,395 shares at $154.9105, and 200 shares at $155.62 in open-market transactions under a Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, she held 120,288 shares of common stock and 48,110 options directly.

Gilead Sciences Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock in an open-market transaction. The sale took place on February 17, 2026, at an average price of $154.43 per share. After this sale, he directly owned 167,779 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on August 29, 2024, and the share balance also reflects purchases through the company’s Employee Stock Purchase Plan.

Gilead Sciences chairman and CEO Daniel P. O'Day reported an automatic insider transaction involving stock options and common shares. On February 5, 2026, he exercised 115,640 non-qualified stock options at a price of $66.01 per share and received the same number of common shares.

That same day, he sold 115,640 shares of Gilead common stock at $150 per share under a Rule 10b5-1 trading plan adopted on February 28, 2025. After these transactions, he directly owned 613,912 shares of Gilead common stock.

Gilead Sciences officer Johanna Mercier, Chief Commercial & Corporate Affairs Officer, reported performance-based stock awards on common shares. On February 3, 2026, she acquired 44,867 shares at $0 following certification that performance goals were met for awards granted in March 2023 and March 2024.

On the same date, 24,800 shares were withheld at $143.28 per share, likely for tax obligations, leaving her with 123,288 shares of Gilead common stock held directly. Portions of the 2024 award will be issued only after additional service requirements are satisfied.

Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported equity-related transactions in company common stock. On February 3, 2026, he acquired 44,867 shares of common stock at $0 per share, tied to performance share awards granted on March 10, 2023 and March 10, 2024.

These awards vested after the Compensation and Talent Committee certified achievement of performance goals, though shares from the March 10, 2024 grant will only be issued once additional service requirements are met. On the same date, he had a disposition coded "F" of 24,802 shares at $143.28 per share. Following these transactions, Dickinson directly owns 170,568 shares of Gilead common stock.

Gilead Sciences Chairman and CEO Daniel P. O'Day reported equity compensation activity involving the company’s common stock. On February 3, 2026, he acquired 131,675 shares at $0 under performance share awards granted in March 2023 and March 2024 after performance goals were certified.

On the same date, 74,461 shares were disposed of at $143.28, typically reflecting shares withheld to cover taxes on the vesting. After these transactions, O'Day directly owned 613,912 shares of Gilead common stock. Portions of the 2024 performance award will only be issued once additional service-vesting requirements are met.

Gilead Sciences Chairman & CEO Daniel O'Day reported planned share sales. On 01/28/2026, he sold 5,032 shares of common stock at a weighted average price of $139.5441 and 4,968 shares at $140.2426 in open-market transactions.

These sales were made under a Rule 10b5-1 trading plan adopted on February 28, 2025. After the transactions, O'Day directly owned 556,698 Gilead shares. The first group of sales occurred at prices ranging from $138.99 to $139.97, and the second from $140.00 to $140.57.

Gilead Sciences Chairman and CEO Daniel P. O'Day reported an automatic option exercise and stock sale. On January 23, 2026, he exercised 115,640 non-qualified stock options at an exercise price of $66.01 per share, acquiring the same number of Gilead common shares. On the same day, he sold 115,640 common shares at a price of $135 per share. After these transactions, he directly owned 566,698 shares of Gilead common stock. The filing states that the transaction was carried out under a Rule 10b5-1 trading plan adopted on February 28, 2025, indicating it was pre-arranged under SEC rules.

Gilead Sciences director Jeffrey Bluestone exercised non-qualified stock options for 5,000 shares of common stock at $67.4500 per share on January 20, 2026, then sold 5,000 shares at $123.5000 per share the same day under a Rule 10b5-1 trading plan adopted on February 13, 2025. After these transactions, he holds 8,920 shares of Gilead common stock directly.

Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported a small, pre-planned stock sale. On January 15, 2026, he sold 3,000 shares of Gilead common stock at a price of $124.31 per share. After this transaction, he continued to beneficially own 150,503 shares of the company’s common stock in direct ownership.

The sale was executed under a Rule 10b5-1 trading plan that was adopted on August 29, 2024, meaning the trade was scheduled in advance under a preset plan rather than being decided at the time of sale.

Gilead Sciences Chief Commercial Officer Johanna Mercier reported a sale of company stock in an insider transaction. On January 15, 2026, she sold 3,000 shares of Gilead Sciences common stock at a price of $124.31 per share, reported under transaction code "S" for a sale. After this transaction, she beneficially owned 103,221 shares of Gilead common stock in direct ownership.

The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan, which was adopted on February 20, 2025. Such plans allow insiders to pre-arrange trades according to preset instructions, providing a structured way to sell shares over time.

Gilead Sciences disclosed that its Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of the company’s common stock on December 15, 2025 at a price of $122 per share. Following this sale, he beneficially owns 153,503 shares, held directly. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Gilead Sciences, Inc. reported an insider stock sale by its Chief Commercial Officer, Johanna Mercier. On 12/15/2025, Mercier sold 3,000 shares of Gilead common stock at $122 per share in a sale transaction coded "S".

After this sale, she beneficially owns 106,221 shares directly. The report notes that the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025, which allows executives to schedule trades in advance.

Gilead Sciences CEO Daniel P. O'Day reported insider stock activity involving restricted stock units linked to Gilead Sciences, Inc. common stock. On 12/10/2025, 10,426 restricted stock units were converted into 10,426 shares of common stock, increasing his directly held shares before a related disposition.

On the same date, 4,931 shares of common stock were disposed of at a price of $ 121.34 per share. After these transactions, O'Day directly owned 576,698 shares of Gilead common stock and 88,070 restricted stock units. Each restricted stock unit represents the right to receive one share, and the units follow a four-year vesting schedule in which 25% vest on the first anniversary of the grant date and the remaining balance vests 6.25% quarterly until fully vested.

Gilead Sciences Chief Commercial Officer Johanna Mercier reported routine equity award activity involving restricted stock units and company shares. On 12/10/2025, 3,842 restricted stock units converted into an equal number of Gilead common shares. On the same date, 1,814 shares of common stock were disposed of in a transaction coded "F," indicating shares were withheld or used to cover tax obligations at a price of $121.34 per share.

After these transactions, Mercier directly beneficially owns 109,221 shares of Gilead common stock and 27,674 restricted stock units. Each restricted stock unit represents the contingent right to receive one share, and the units follow a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining units vesting 6.25% quarterly until fully vested.

Gilead Sciences, Inc. (GILD) reported an insider transaction by its Chief Financial Officer. On 11/17/2025, the CFO sold 2,500 shares of Gilead common stock at a price of $125.23 per share in an open-market sale coded as an "S" transaction. After this sale, the reporting person beneficially owns 154,555 shares of Gilead common stock in direct ownership. The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, which is designed to allow insiders to trade according to predetermined instructions.

Gilead Sciences, Inc. (GILD) reported insider activity by its Chief Commercial Officer, Johanna Mercier. On 11/17/2025, she exercised a non-qualified stock option to acquire 25,000 shares of common stock at an exercise price of $66.64 per share, increasing her direct holdings before any sales.

That same day, she reported open-market sales of 25,524 shares at a weighted-average price of $125.8251 and 2,476 shares at a weighted-average price of $126.2575, all under a Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, she directly owned 107,193 shares of Gilead common stock and 73,110 non-qualified stock options.

Gilead Sciences (GILD) disclosed insider activity by its EVP, Corporate Affairs & GC, on 11/12/2025 pursuant to a Rule 10b5‑1 trading plan adopted on August 13, 2025. The officer exercised non‑qualified stock options and sold the resulting shares the same day.

Exercises were for 17,181 shares at $75.12, 35,965 shares at $60.75, and 500 shares at $60.75, followed by sales of equal amounts. Sale prices included $124 and weighted‑average prices of $122.302 and $122.904, with transaction ranges of $121.87–$122.83 and $122.88–$122.92. After these trades, 43,676 common shares were beneficially owned directly.

Gilead Sciences (GILD) insider filing: Chairman & CEO Daniel P. O’Day reported open‑market sales totaling 10,000 shares on 10/28/2025 under a Rule 10b5‑1 trading plan adopted on February 28, 2025. The transactions were coded “S”.

He sold 7,978 shares at an average price of $119.5371 and 2,022 shares at $118.8223. Following the sales, he beneficially owns 581,203 shares directly, down from 583,225 before these trades. The filing notes price ranges for each trade, with full breakdowns available upon request to the company, the SEC, or shareowners.

Gilead Sciences (GILD): Officer equity transaction reported

On 10/25/2025, an officer of Gilead Sciences (title: EVP, Corporate Affairs & GC) reported the conversion of 515 restricted stock units into common stock (transaction code M) and the disposition of 241 shares at $120.94 (transaction code F). Following these transactions, the officer directly owned 43,676 shares of common stock.

The filing also shows 19,816 restricted stock units beneficially owned after the reported transaction. The RSUs vest over four years: 25% on the first anniversary of grant, then 6.25% quarterly until fully vested.

Gilead Sciences (GILD) disclosed an insider transaction by Chief Commercial Officer Johanna Mercier. On 10/15/2025, she sold 3,000 shares of common stock at $118.08 per share (transaction code S). After the sale, she beneficially owned 110,193 shares, held directly.

The filing states the trade was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Gilead Sciences (GILD) CFO Andrew D. Dickinson reported an open‑market sale of 2,500 shares of common stock at $118.08 on October 15, 2025. The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on August 29, 2024.

Following the transaction, Dickinson beneficially owns 157,055 shares, held directly.